Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
US9387265B2 · kind B2 · utility
1Cited by
6References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 8, 2014 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Sep 8, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.